Pediatric Heart Transplant: Initial Experience in a Tertiary Center in Brazil
| Autor: | Cajueiro, Francisco Candido Monteiro, Croti, Ulisses Alexandre, Barufi, Alexandra Regina Siscar, Bodini, André Luís de Andrade, Postigo, Karolyne Barroca Sanches, Marchi, Carlos Henrique De, Santos, Fernando Cesar Gimenes Barbosa, Beani, Lilian, Borim, Bruna Cury, Godoy, Moacir Fernandes, Moscardini, Airton Camacho |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Brazilian Journal of Cardiovascular Surgery v.37 n.3 2022 Brazilian Journal of Cardiovascular Surgery Sociedade Brasileira de Cirurgia Cardiovascular (SBCCV) instacron:SBCCV Brazilian Journal of Cardiovascular Surgery, Volume: 37, Issue: 3, Pages: 281-291, Published: 03 JUN 2022 |
| Popis: | Introduction: Pediatric heart transplantation is the definitive therapy for children with end-stage heart failure. This paper describes our initial experience in pediatric heart transplantation in a tertiary center in Brazil Methods: This is a historical prospective descriptive cohort study based on a review of the medical records of children undergoing heart transplantation at Hospital de Base and Hospital da Criança e Maternidade de São José do Rio Preto. Variables were displayed as frequency, mean, or median. Statistical analysis and Kaplan-Meier actuarial curve were obtained with the aid of Microsoft® Excel® 2019 and STATSDirect version 3.3.5. Results: Between January 2010 and December 2020, ten children underwent bicaval orthotopic heart transplantation, 30% of which were under one year of age. Nine patients had end-stage heart failure (International Society for Heart and Lung Transplantation-Heart Failure D) and 50% of the recipients were transplanted under conditions of progressive clinical deterioration (Interagency Registry for Mechanically Assisted Circulatory Support ≤ 2). Forty percent of the recipients had a panel-reactive antibody > 20% on virtual crossmatch. In the postoperative period, 80% of patients required high dose of inotropic support (vasoactive-inotropic score > 10) for > 48 hours. The death-free survival rate at 131 months was 77.1±14.4%. Most patients (88.9%) in late follow-up had an episode of active cytomegalovirus infection. Cellular rejection, with or without clinical repercussion, was present in 44.4% of the patients. Conclusion: Pediatric heart transplantation produces acceptable and feasible outcomes as definitive therapy for children with end-stage heart failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|